Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission

Trial Profile

Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Dihydroartemisinin/piperaquine (Primary)
  • Indications Malaria
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms ECG-Lihir
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 19 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top